Skip to main content
Vinod Vathipadiekal

Vinod Vathipadiekal

Board Director, Aldebaran Therapeutics
Vinod has more than a decade of experience in the RNA medicine field from Pharma and Biotech, where he led multiple ASO drugs into clinical trials. Vinod currently serves as a board director for Aldebaran therapeutics, a company focused on developing best-in-class precision ASO therapeutics for Ocular indications. He also leads the RNA Medicine department at Alloy Therapeutics. Previously, he headed the ASO therapeutic programs in Leal Therapeutics (VP, Head of Nucleic Acid Therapeutics) and Eisai (Director, Head of ASO Therapeutics).